Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207866 | 0.86 | GABRA1 (0.35) | ALDH1A1KMT2AKDM4EAGTR1GABRA1 | |
| SCHEMBL5213384 | 0.86 | RXRA (0.47) | ALDH1A1PKMKMT2AKDM4E | |
| SCHEMBL14609752 | 0.85 | TSPO (0.37) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL5215764 | 0.83 | NPC1 (0.48) | ALDH1A1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL5211701 | 0.83 | MKNK1 (0.42) | ALDH1A1KMT2AMAPK1 | |
| SCHEMBL5212575 | 0.83 | ENPP2 (0.49) | ALDH1A1KMT2A | |
| SCHEMBL5209936 | 0.83 | LMNA (0.50) | ALDH1A1PKMKMT2ARAB9AMAPK1 | |
| SCHEMBL5212489 | 0.82 | RXRA (0.43) | KMT2A | |
| SCHEMBL5212748 | 0.81 | LMNA (0.51) | KMT2A | |
| SCHEMBL5213449 | 0.81 | RXRA (0.43) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | ALDH1A1 1651/4885PKM 3693/4885KMT2A 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.